Disc Medicine (IRON) Net Cash Flow (2020 - 2026)
Disc Medicine (IRON) reported Net Cash Flow of -$2.2 million for Q1 2026, up 96.8% year-over-year from -$1.1 million in Q1 2025, and up 95.49% on a QoQ basis from -$49.5 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Net Cash Flow data on file, last reported at -$2.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 96.8% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.8 million (up 84.65% YoY) and the FY2025 annual result came in at -$101.3 million, up 39.69% from the prior year.
- Net Cash Flow advanced to -$2.2 million in Q1 2026 per IRON's latest filing, from -$49.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $141.1 million in Q2 2023 and bottomed at -$88.0 million in Q3 2024.
- The 5-year median for Net Cash Flow is -$9.1 million (2022), against an average of $55411.8.
- The widest annual swing landed in 2023, when Net Cash Flow surged 1646.0%; it then tumbled 24413.37% in 2025.
- Tracing IRON's Net Cash Flow over 5 years: stood at $139.1 million in 2022, then slumped by 107.22% to -$10.0 million in 2023, then jumped by 97.99% to -$202000.0 in 2024, then plunged by 24413.37% to -$49.5 million in 2025, then soared by 95.49% to -$2.2 million in 2026.
- Per Business Quant, the three latest IRON Net Cash Flow figures stand at -$2.2 million (Q1 2026), -$49.5 million (Q4 2025), and $13.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.23 Mn |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -49.52 Mn |
| Dec 31, 2025 | -49.52 Mn |
| Sep 30, 2025 | 13.33 Mn |
| Sep 30, 2025 | 13.33 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | -69.76 Mn |
| Mar 31, 2025 | -69.76 Mn |
| Dec 31, 2024 | -202,000.00 |
| Dec 31, 2024 | -202,000.00 |
| Sep 30, 2024 | -88.03 Mn |
| Sep 30, 2024 | -88.03 Mn |
| Jun 30, 2024 | -61.95 Mn |
| Jun 30, 2024 | -61.95 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Dec 31, 2023 | -10.04 Mn |
| Dec 31, 2023 | -10.04 Mn |
| Sep 30, 2023 | -7.06 Mn |
| Sep 30, 2023 | -7.06 Mn |
| Jun 30, 2023 | 141.12 Mn |
| Jun 30, 2023 | 141.12 Mn |
| Mar 31, 2023 | 41.81 Mn |
| Mar 31, 2023 | 41.81 Mn |
| Dec 31, 2022 | 139.14 Mn |
| Dec 31, 2022 | 139.14 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Jun 30, 2022 | -9.13 Mn |
| Jun 30, 2022 | -9.13 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Dec 31, 2021 | -83.24 Mn |
| Dec 31, 2021 | -83.24 Mn |
| Sep 30, 2021 | -17.35 Mn |
| Sep 30, 2021 | -17.35 Mn |
| Jun 30, 2021 | -17.51 Mn |
| Jun 30, 2021 | -17.51 Mn |
| Mar 31, 2021 | 180.48 Mn |
| Mar 31, 2021 | 180.48 Mn |
| Dec 31, 2020 | 1.21 Mn |
| Dec 31, 2020 | 1.21 Mn |
| Sep 30, 2020 | 1.44 Mn |
| Sep 30, 2020 | 1.44 Mn |
| Jun 30, 2020 | -7.02 Mn |
| Jun 30, 2020 | -7.02 Mn |
| Mar 31, 2020 | 10.21 Mn |
| Mar 31, 2020 | 10.21 Mn |